Updated Efficacy and Safety Results of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the Ongoing Phase 1 CaDAnCe-101 Study

This presentation reports updated results on a novel BTK degrader therapy for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The treatment showed strong anti-tumor activity across different patient subgroups, including those with prior therapies and resistance mutations, while maintaining a manageable safety profile without new concerns about toxicities. Overall, the findings suggest this therapy is a promising option that continues to be evaluated in ongoing clinical studies.